1 min read
Add as a preferred source on Google

Apimeds Pharmaceuticals US, Inc. Posts $2.89 Million Revenue and $7.68 Diluted GAAP EPS

Third-quarter basic GAAP EPS was $19.13.

Apimeds Pharmaceuticals US, Inc. recorded $2.89 million in third-quarter revenue, with basic GAAP EPS of $19.13 and diluted GAAP EPS of $7.68.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…